Session Information
Date: Sunday, November 13, 2022
Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations
Session Type: Poster Session C
Session Time: 1:00PM-3:00PM
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management of the disease. The aim of this study is to describe different SLE clusters according to sociodemographic variables and cumulative clinical and serological variables.
Methods: GLADEL 2.0 (GLADEL, Grupo Latino Americano De Estudio del Lupus) is an ongoing observational prevalent and incident cohort initiated in 2019. Patients in this cohort were categorized according to renal involvement: Group I (Lupus Nephritis (LN) never); Group II (inactive LN; prevalent renal involvement in the past and currently inactive); Group III (active LN; prevalent renal involvement and currently active) and Group IV (active LN; incident renal involvement). The variables chosen at cohort entry to stratify patients with similar profiles and construct the clusters were selected from the sociodemographic and cumulative clinical and serological variables. Hierarchical cluster analyses were performed by the Ward method on a distance matrix using the Gower’s method. A p-value < 0.05 was considered significant.
Results: A total of 560 SLE patients were included in this analysis. Three clusters were identified. Cluster 1 (n=269) was characterized by more cutaneous, articular, renal and serosal involvement; the most important serological manifestation was positive anti-dsDNA. Cluster 2 (n=194) was represented by patients who rarely had renal involvement and the most frequent clinical manifestations were cutaneous and hematological; the most frequent serological manifestations were the presence of antiphospholipid antibodies (aPLs). Cluster 3 (n=97) was characterized by a lower frequency of clinical and serological involvements, with the exception of neurological domain. Clusters 1 and 2 share hematologic manifestations and hypocomplementemia. No major differences according of ethinicity were found among clusters (Table 1).
Conclusion: In this Latin-American cohort, three patient clusters were identified. Cluster 1 patients were characterized by renal, articular, cutaneous and serositis involvement and anti-dsDNA antibodies and hypocomplementemia, Cluster 2 patients were characterized by hematologic and cutaneous involvement and antiphospholipid antibodies and hypocomplementemia. On the contrary, Cluster 3 patients presented fewer serological findings but a higher frequency of neurological involvement. Follow up of patients in this cohort will allow for elucidation of the relationship of these clusters with SLE outcomes. Autoantibodies assessed in a central laboratory may further help in the identification of these clusters.
To cite this abstract in AMA style:
Quintana R, Nieto R, Scolnik M, Meras N, Otaduy C, Sattler M, González Lucero L, Perez N, Silva A, Monticielo O, Duarte A, Reis Neto E, Mimica M, Aroca Martinez G, Quintana-Lopez G, Moreno Alvarez M, Saavedra Salinas M, Portela M, Silveira L, García Valladares I, Abud-Mendoza C, Esquivel-Valerio J, Duarte M, Muñoz Louis R, Juárez V, Ferreira Borba Neto E, Catoggio L, Alarcón G, Puerta J, Harvey G, Novati E, Arturi V, Grageda W, Pisoni C, Machado Riobeiro F, Figueiredo Neves Yuki E, Guerra Herrera I, Tobón G, Cadena Bonfanti A, Fragoso-Loyo H, de Martinez M, Mora Trujillo C, Ugarte-Gil M, Zavala Flores E, Robaina R, Silveira G, Zazzetti F, Orillion A, Pons-Estel G, Pons-Estel B, Sbarigia U. Latin-American Systemic Lupus Erythematosus Clusters [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/latin-american-systemic-lupus-erythematosus-clusters/. Accessed .« Back to ACR Convergence 2022
ACR Meeting Abstracts - https://acrabstracts.org/abstract/latin-american-systemic-lupus-erythematosus-clusters/